nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo searchdiv qikanlogo popupnotification paper paperNew
2023 05 v.44 506-511
异常糖链糖蛋白联合血清肿瘤标志物对非小细胞肺癌的早期诊断价值

Summary

Note: Please note that the following content is generated by AI. CNKI does not take any responsibility related to this content.
基金项目(Foundation):
邮箱(Email): xueli8836@163;
DOI:
2 201 8
阅读 下载 被引

工具集

引用本文 下载本文
PDF
引用导出 分享

    扫码分享到微信或朋友圈

使用微信“扫一扫”功能。
将此内容分享给您的微信好友或者朋友圈
摘要:

目的 探讨异常糖链糖蛋白(TAP)联合血清肿瘤标志物对非小细胞肺癌(NSCLC)的早期诊断价值。方法 回顾性分析南通市中医院2019年1月至2021年10月收治的80例NSCLC患者的病历资料,为NSCLC组,均以病理学检查为金标准,另选取该院同期80例肺部良性病变患者的病历资料进行对照,为良性病变组。收集并整理所有受试者的临床资料,分析血清肿瘤标志物[神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)]和TAP水平。采用Logistic多因素回归分析探究NSCLC发病的影响因素,受试者操作特征(ROC)曲线判定2组患者血清肿瘤标志物及TAP对不同分期NSCLC的诊断效能。结果 NSCLC组患者TAP、NSE、CYFRA21-1、CEA、CA125水平均高于良性病变组(P<0.05)。NSCLC组患者吸烟史及从事高油烟或高密度粉尘等相关工作职业所占比例均高于良性病变组(P<0.05)。Logistic多因素回归分析结果显示,吸烟史、从事高油烟或高密度粉尘等相关工作职业及血液TAP、NSE、CYFRA21-1、CEA、CA125水平升高均为NSCLC发病的影响因素(P<0.05)。ROC分析显示,TAP、NSE、CYFRA21-1、CEA、CA125单一诊断Ⅰ~Ⅳ期NSCLC患者的灵敏度中TAP、NSE诊断效能较高。TAP联合NSE诊断Ⅰ~Ⅳ期NSCLC患者的AUC分别为0.642、0.679、0.774、0.791,4项血清肿瘤标志物和TAP联合诊断Ⅰ~Ⅳ期NSCLC患者的曲线下面积(AUC)分别为0.649、0.683、0.785、0.794。结论 TAP联合NSE诊断Ⅰ~Ⅳ期NSCLC的诊断效能较高,具有广阔的临床应用前景。

Abstract:

Objective To investigate the early diagnosis value of tumor abnormal protein(TAP) combined with serum tumor markers in early diagnosis of non-small cell lung cancer(NSCLC).Methods The medical records of 80 patients with NSCLC admitted to the hospital from January 2019 to October 2021 were analyzed retrospectively,with the pathological examination as the gold standards.The medical records of another 80 patients with benign lung lesions within the same time span were selected for control.The clinical data of all the subjects were collected and sorted out,and the expression levels of serum tumor markers,including neuron specific enolase(NSE) and cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125) and TAP were detected and analyzed.Logistic multivariate regression analysis was used to analyze the influencing factors of NSCLC,and the working characteristic curve(ROC) of the subjects was used to determine the diagnostic efficacy of serum tumor markers and TAP at different stages of NSCLC.Results The levels of TAP,NSE,CYFRA21-1,CEA and CA125 in the NSCLC group were all higher than those in the benign group(P<0.05).The proportions of those with a smoking history and such related occupations as high-oil-smoke or high-density dust in the NSCLC group were all higher than those in the benign group(P<0.05).Logistic multivariate regression analysis showed that those with a smoking history,occupations with high-oil-smoke or high-density dust,and increased expression levels of TAP,NSE,CEA,CA125 and CYFRA21-1 were all influential factors for the onset of NSCLC(P<0.05).ROC analysis showed that the indexes of TAP,NSE,CYFRA21-1,CEA and CA125 displayed relatively higher diagnostic efficiency in single diagnosis of stage I-IV NSCLC in terms of sensitivity.The AUCs of TAP combined with NSE in the diagnosis of stage I-IV NSCLC were 0.642,0.679,0.774 and 0.791 respectively,and the AUCs of the five indexes in combined diagnosis of NSCLC were 0.649,0.683,0.785 and 0.794 respectively.Conclusion TAP combined with NSE displays high efficiency in the diagnosis of stage I-IV NSCLC,therefore it promises a good future for clinical application.

参考文献

[1] Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer(NSCLC)[J].Cancer, 2020, 126(2):260-270.

[2]丁薇,黄佳茹,刘明,等.支气管肺泡灌洗液及血清中HGF、TGF-β1水平对早期非小细胞肺癌的诊断价值[J].中华航海医学与高气压医学杂志,2019, 26(5):435-438.

[3] Altorki NK, Markowitz GJ, Gao D, et al.The lung microenvironment:an important regulator of tumour growth and metastasis[J].Nat Rev Cancer, 2019, 19(1):9-31.

[4]刘一胜,李小平,鲍方,等.亚肺叶切除与肺叶切除对T1a,bN0M0期非小细胞肺癌预后的影响[J].海军医学杂志,2019, 40(3):233-236.

[5] Jain D, Nambirajan A, Borczuk A, et al.Immunocytochemistry for predictive biomarker testing in lung cancer cytology[J].Cancer Cytopathol, 2019, 127(5):325-339.

[6] Schildhaus HU. Immunohistochemistry-based predictive biomarkers for lung cancer[J].Pathologe, 2020, 41(1):21-31.

[7]郭娜,周小果.肺癌三项肿瘤标记物联合肿瘤异常蛋白诊断老年肺癌[J].中国老年学杂志,2019, 39(6):1338-1340.

[8]董芸,袁峥玺,姚原.肿瘤标志物SCC-Ag、Cyf21-1、CEA、ProGRP及NSE联合检测在肺癌诊断中的应用[J].中国实验诊断学,2019, 23(3):384-386.

[9]余剑桥,周俊,付海琴.CYFRA211、LDH联合NSE检测辅助诊断肺癌及与TNM分期的关系[J].分子诊断与治疗杂志,2021, 13(10):1619-1622.

[10]中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2019版)[J].中华肿瘤杂志,2020, 42(4):257-287.

[11]黄文铖,黄馨莹,郑建明,等.CT定位下活检联合血清肿瘤标志物检测对周围型肺癌的诊断价值分析[J].海军医学杂志,2019, 40(5):459-462, 467.

[12] Zito MF, Bianco R, Accardo M, et al.Molecular heterogeneity in lung cancer:from mechanisms of origin to clinical implications[J].Int J Med Sci, 2019, 16(7):981-989.

[13]尤向辉,刘冲,王希,等.肿瘤标志物诊断肺癌转移的临床价值[J].现代肿瘤医学,2021, 29(15):2624-2628.

[14]彭峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020, 49(7):851-854.

[15] Pellini B, Szymanski J, Chin RI, et al. Liquid biopsies using circulating tumor DNA in non-small cell lung cancer[J].Thorac Surg Clin, 2020, 30(2):165-177.

[16] Guibert N, Pradines A, Favre G, et al.Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages[J].Eur Respir Rev, 2020, 29(15):190-191.

[17]吴海波,刘若男,高敏,等.非小细胞肺癌患者血清肿瘤异常蛋白的表达与化疗疗效的相关性[J].临床肺科杂志,2020,25(9):1395-1399.

[18]张红军,房延凤,谢永宏,等.肺癌患者异常糖链糖蛋白与传统肿瘤标志物的相关性分析[J].中华肺部疾病杂志(电子版),2019, 12(1):24-27.

[19]刘哲,郝媛媛,卢畅.肺癌患者TAP表达水平与其预后的相关性[J].中国实验诊断学,2020, 24(8):1263-1265.

[20]王茜,夏睿,董惠霞,等.ProGRP、NSE、CEA、CYFRA21-1、SCC单独及联合检测在肺癌鉴别诊断中的价值[J].临床检验杂志,2020, 38(12):930-932.

[21]应晓珍,林霞,鲍黎明,等.非小细胞肺癌患者血清癌胚抗原、神经元特异性烯醇化酶、胃泌素释放肽前体水平与患者预后关系研究[J].中国卫生检验杂志,2019, 29(10):1211-1213.

[22]盛俊卿,李卫星,贾祯,等.多层螺旋CT灌注成像联合血清CYFRA21-1、CEA、NSE对周围型非小细胞肺癌的诊断价值[J].解放军医学杂志,2020, 45(5):542-546.

[23]张晶,赖飞,蔡建兴,等.血清淀粉样蛋白A联合细胞角蛋白片段-1检测对非小细胞肺癌的诊断价值[J].中国老年学杂志,2019, 39(22):5493-5496.

[24]van Delft FA,Schuurbiers M,Muller M,et al. Modelingstrategies to analyse longitudinal biomarker data:anillustration on predicting immunotherapy non-response in non-small cell lung cancer[J].Heliyon,2022,8(10):1093210932.

[25] Li Z,Zhao J. Clinical efficacy and safety of crizotinib andalectinib in alk-positive non-small cell lung cancer treatmentand predictive value of CEA and CAl25 for treatment efficacy[J].Am J Transl Res,2021,13(11):13108-13116.

[26]袁懋绣,兰彩云,周建中,等.胸腔镜手术治疗早期肺癌的效果及对血清CEA、CA125、PCT、CRP水平的影响[J].中国老年学杂志,2020, 40(20):4310-4312.

[27] Klebe S, Leigh J, Henderson DW, et al. Asbestos, smoking and lung cancer:an update[J]. Int J Environ Res Public Health, 2019, 17(1):258-259.

[28] Petit P, Maitre A, Persoons R, et al.Lung cancer risk assessment for workers exposed to polycyclic aromatic hydrocarbons in various industries[J].Environ Int, 2019, 124(7):109-120.

基本信息:

DOI:

中图分类号:R734.2

引用信息:

[1]薛漓,丁好,石婧奇.异常糖链糖蛋白联合血清肿瘤标志物对非小细胞肺癌的早期诊断价值[J].海军医学杂志,2023,44(05):506-511.

基金信息:

文档文件

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文